Free Shipping on purchases over €100

Blemil Confort 2 Confort Evolution, 800 g

Blemil Confort 2 Confort Evolution, 800 g is a follow-on formula with high tolerance and digestibility, indicated for the nutritional management of mild digestive discomfort such as colic, constipation, regurgitations and other moderate digestive disorders, when they extend beyond the first months of life.

SKU: BL8426594143534
Sold out
28.20
€31.33
Temporarily sold out

Subscribe and we will notify you when it becomes available again.

Pharmaceutical Care

Safe medication sales

Secure shipping

INFO AND TECHNICAL SPECIFICATIONS

Blemil 2 Comfort Evolution is a follow-on formula with high tolerance and digestibility, indicated for the nutritional management of mild digestive discomfort such as colic, constipation, regurgitations and other moderate digestive disorders, when they extend beyond the first months of life.


Its main benefits and nutritional characteristics are as follows:


Optimal protection: Enhanced symbiotic effect on the intestinal microbiota.
- With IM1® Confort: Exclusive combination of 4 major probiotic species found in breast milk and the digestive system of breastfed infants.
Prevention of intestinal infections
- Bifidobacterium infantis IM1®, proven efficacy against gastrointestinal pathogens
- Lactobacillus rhamnosus HN001®, reduces allergic symptoms


Anti-colic effect


- Bifidobacterium breve Hereditum, derived from breast milk and clinically proven to improve colic in infants
- Lactobacillus reuteri, the species with the most evidence in the improvement of infant colic.
- With 5 HMO: Synergistic effect with the probiotics present in the formula, favouring their implantation. Bifidogenic and antimicrobial effect. With the ability to modulate the immune response and reduce the risk of infections.
- With prebiotic oligosaccharides, inulin, which stimulates the establishment of an intestinal microbiota with a high bifidobacteria content, as a mechanism of protection against
gastrointestinal infections and allergies.


Anti-colic effect
- High digestibility: 100% partially hydrolysed whey proteins, improving digestibility, absorption and tolerance in infants with some degree of intolerance to milk proteins.
- Excellent tolerance: low lactose content (44%), reducing flatulence and abdominal discomfort, the cause of crying and discomfort.
Anti-constipation effect
- With inulin as a prebiotic fibre. Long-chain fructooligosaccharide (FOS) with the ability to stimulate hydration and increase stool volume.
- High concentration of ß-palmitate, from milk fat, promoting intestinal transit and providing a pleasant aroma and flavour.


Anti-regurgitant effect


- Reduction of mild regurgitations: with corn starch, helping to reduce crying and discomfort.


PRODUCT INDICATIONS


Blemil 2 confort Evolution is a follow-on formula especially indicated for:
- Nutritional management of infant colic-type digestive symptoms, combined or not with mild constipation.
- Moderate digestive disorders with excessive gas formation in the digestive tract and mild regurgitations.
- Infants with low lactose tolerance.
- Mixed breastfeeding with HA milk.
- Mild non-specific digestive discomfort requiring a high tolerance formula.
Blemil 2 confort Evolution is a dietetic food intended for a special group of infants, indicated from the 6th month of age as part of a diversified diet.
Blemil 2 confort Evolution should be used as part of a diversified diet and should not be used as a substitute for breast milk during the first 6 months of life.
Breast milk is the best food for infants during the first months of life, and when this is not possible, it is up to the paediatrician or health professional monitoring growth and development to recommend the most appropriate one.

Tecnical specifications card

Pharmaceutical advice

You can now consult our team with any questions you may have. We remind you that our chatbot is also available for simpler queries.

Ask us
Newsletter

Don’t miss anything

Stay up to date with the latest advances in health, discounts, and pharmaceutical news.